Key result
Novel biomarkers like troponins and natriuretic peptides enhance diagnosis and prognosis in HF and AMI.
Why the study?
Numerous biomarkers pertaining to cardiovascular diagnosis, prognosis, and risk prediction have been identified, but few have made their way to clinical practice.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Reinforces troponin and natriuretic peptide roles in HF and AMI; leaves open incremental value of newer biomarkers pending prospective trials.
Measurement of biomarkers has revolutionized the work-up of patients with suspected cardiovascular disease. The most widely used contemporary cardiovascular biomarkers are the natriuretic peptides in the diagnosis and prognosis of heart failure and cardiac troponins in the diagnosis of acute myocardial infarction. Numerous other biomarkers pertaining to diagnosis, prognosis, and risk prediction have been identified, but few have made their way to clinical practice. In this review, we will initially describe the fundamental approach to evaluate a novel biomarker. Before implementation of a biomarker into clinical practice, several stringent criteria related to its clinical utility are required. Essential statistical metrics such as discrimination, calibration, and reclassification are required to properly evaluate prediction models. We will then discuss the biomarkers according to main groups of cardiovascular pathology:1. myocardial injury (cardiac troponins, heart-type fatty acid-binding protein, cardiac myosin binding protein-C);2. myocardial stress (A-type and B-type natriuretic peptides, mid-regional pro-adrenomedullin, copeptin); 3. inflammation (C-reactive protein, interleukin 6, growth differentiation factor 15, soluble suppressor of tumorigenicity 2, galectin-3);4. platelet activation (soluble CD40 ligand, P-selectin);5. plaque instability (lipoprotein-associated phospholipase A₂, matrix metalloproteinase-9);6. systemic stress (catecholamines, granin proteins);7. calcium homeostasis (secretoneurin). Finally, we will discuss novel applications of cardiovascular biomarkers, more specifically prediction of ventricular arrhythmias, and the use of biomarkers in composite risk prediction models.
No takes yet. Share an insight, caveat, or question.
Lyngbakken et al. (2018) studied this question. Novel cardiovascular biomarkers, such as cardiac troponins and natriuretic peptides, enhance diagnosis and prognosis in heart failure and acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: